HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

[JD Health (6618 HK, BUY, TP HK$65) TP Change]: Benefit of Alternative Channel Starts to Show

JD Health (6618.HK) 23H1 - The Beautiful Story Is Over; It's Time to Face Reality

ClouDr Group (9955.HK) 23H1 - Turning Losses into Profits Is Within Reach

JD Health (6618.HK) - Business Transformation Is Still Difficult

JD Health (6618.HK) - It's Time to Reassess the Business Prospects and Valuation

Ping An Good Doctor - Strategic Transformation Still in Progress

China Traditional Chinese Medicine (570.HK) - The Privatization Rumor and the Outlook

Equity Bottom-Up

JD Health International  / Equity Bottom-Up

<ul>
<li>The previously stockpiled drugs/medical devices require a long cycle of digestion. As the industry beta brought by COVID-19 dividend would fade away, JD Health's performance growth could slow down accordingly.</li>
<li>Although JD Health divides its buiness into product revenue and service revenue, drug/product sales are still the underlying logic and business model, which is difficult to maintain high growth expectations.</li>
<li>Current valuation is in reasonable range. Since JD Health will be added to HSI INDEX, it could help boost share price. However, if business transformation fails, high valuation is unsustainable. </li>
</ul>


The previously stockpiled drugs/medical devices require a long cycle of digestion. As the industry beta brought by COVID-19 dividend would fade away, JD Health's performance growth could slow down accordingly.
Although JD Health divides its buiness into product revenue and service revenue, drug/product sales are still the underlying logic and business model, which is difficult to maintain high growth expectations.
Current valuation is in reasonable range. Since JD Health will be added to HSI INDEX, it could help boost share price. However, if business transformation fails, high valuation is unsustainable. 


JD Health (6618.HK) 23Q1 - As Industry Beta Fades, the Expectation Reversal Has yet to Come